Compare LFST & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | TARS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.7B |
| IPO Year | 2021 | 2020 |
| Metric | LFST | TARS |
|---|---|---|
| Price | $10.99 | $59.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $9.83 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 3.4M | 1.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,424,285,000.00 | $451,360,000.00 |
| Revenue This Year | $17.18 | $56.43 |
| Revenue Next Year | $14.02 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 13.85 | ★ 146.71 |
| 52 Week Low | $3.74 | $38.51 |
| 52 Week High | $11.76 | $85.25 |
| Indicator | LFST | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 59.97 | 47.34 |
| Support Level | $6.23 | $56.05 |
| Resistance Level | $11.69 | $67.14 |
| Average True Range (ATR) | 0.37 | 3.32 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 45.77 | 37.69 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.